Health and Fitness Health and Fitness
Fri, March 11, 2011
[ Fri, Mar 11th 2011 ] - Market Wire
Covidien????????????????FDA??
Thu, March 10, 2011
[ Thu, Mar 10th 2011 ] - Market Wire
Sunset Cove increases financing

Inhibitex to Present at the ROTH 23rd Annual Growth Stock Conference


Published on 2011-03-10 08:41:20 - Market Wire
  Print publication without navigation


ATLANTA--([ BUSINESS WIRE ])--Inhibitex, Inc. (Nasdaq: INHX), today announced that Russell Plumb, president and chief executive officer, will present an overview of the Company and an update of its pipeline of differentiated anti-infective compounds at the ROTH 23rd Annual Growth Stock Conference on March 15, 2011 at 2:30 PM (PST). The conference is being held at the Ritz Carlton Laguna Niguel in Dana Point, California.

About Inhibitex

Inhibitex, Inc., is a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Companya™s clinical-stage pipeline includes FV-100, a nucleoside inhibitor in Phase II for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in Phase 1b for the treatment of chronic hepatitis C infections. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM® protein platform to Pfizer for the development of a staphylococcal vaccine, which is currently being evaluated in a Phase 1 clinical trial. For additional information about the Company, please visit [ www.inhibitex.com ].

Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex, Inc.